Open until 6:00pm : 01582 842096
VioVet Insurance
FREE DELIVERY on most orders over £29

Finadyne for Horses

  • Paste » 10g Syringe (Pack of 6) £67.65
  • Solution for Injection » 50ml £18.18
  • Solution for Injection » 100ml £35.16

Selection of 3 products from

£18.18 to £67.65

Description

Finadyne is a powerful anti-inflammatory and pain relieving drug, usually used for musculo-skeletal problems and joint injuries in horses. Finadyne also has anti-endotoxic and anti-fever properties, so can be used as an aid in other medical conditions and infections. Finadyne is normally given once daily for up to five days.

Finadyne 5% w/w Oral Paste

Presentation

Syringe with white to off-white oral paste containing 5% w/w Flunixin (as Flunixin meglumine).

Uses

For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

Dosage and administration

For oral administration only.

1.1 mg flunixin per kg bodyweight once daily for up to 5 days according to clinical response.

Each syringe is sufficient for one day’s treatment for a 445 kg (1000 lb.) horse. The syringe is calibrated in 100 kg increments to facilitate dosing of horses of different weights.

Contra-indications, warnings, etc

Flunixin meglumine is a non-steroidal anti-inflammatory drug.

Do not administer to pregnant mares. Safety studies in pregnant mares have not been conducted.

Do not exceed the stated dose or duration of treatment.

Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is hypersensitivity to the product.

Do not administer other NSAID’s concurrently or within 24 hours of each other.

Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock.

Avoid use in dehydrated, hypovolaemic or hypersensitive animals as there is a potential risk of increased renal toxicity.

Non-steroidal anti-inflammatory drugs are not permitted substances under the rules of racing and under rules covering other competitive events. The Royal College of Veterinary Surgeons has given guidance to the Veterinary profession regarding the use of anti-inflammatory drugs in competing horses. It states that if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing he should feel sure he has catered for all but the most exceptional case.

Use in animals less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.

It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.

NSAID’s can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.

Overdosage studies in the target species have shown the product to be well-tolerated. Overdosage is associated with gastrointestinal toxicity.

Interactions

Concurrent administration of potentially nephrotoxic drugs should be avoided.

Some NSAIDs may be highly bound to plasma proteins and may compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations which can lead to toxic effects.

Operator warnings

Avoid contact with eyes and direct contact with skin. Gloves should be worn during application.

In the case of accidental contact with eyes, rinse immediately with plenty of water and seek medical advice.

The product may cause reactions in sensitive individuals. If you have known hypersensitivity to non-steroidal anti-inflammatory products, do not handle the product. Reactions may be serious.

Wash hands and exposed skin after use.

Withdrawal period(s)

Not to be used in horses intended for human consumption.

Treated horses may never be slaughtered for human consumption.

The horse must have been declared as not intended for human consumption under national horse passport legislation.

For animal treatment only. Keep out of the reach and sight of children.

Pharmaceutical precautions

Do not store above 25°C. Do not freeze. Replace cap after use.

Disposal advice

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

POM-V

Packaging Quantities

Carton containing 6 syringes.

10 g or 30 g natural low density white polyethylene syringe barrel and polypropylene dial-a-dose plunger with low density polyethylene cap and plunger seal.

Not all pack sizes may be marketed.

Further information

Nil.

Marketing authorisation number

Vm 00201/4012.

Finadyne 50 mg/ml solution for injection

Qualitative and quantitative composition

Active substance

Flunixin (as Flunixin Meglumine ) 50 mg

Excipients: Phenol (preservative) 5 mg

For a full list of excipients, see section "Pharmaceutical Particulars".

Pharmaceutical form

Solution for injection

Clinical particulars

Target species

Cattle, pigs and horses.

Indications for use

In Cattle: For the control of acute inflammation associated with respiratory disease. Finadyne has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog Fever). Finadyne Solution may be used as adjunctive therapy in the treatment of acute mastitis.

In Horses: For the alleviation of inflammation and pain associated with musculo-skeletal disorders. For the alleviation of visceral pain associated with colic in the horse.

In Pigs: For use as an adjunctive therapy in the treatment of swine respiratory diseases.

Contra-indications

Do not exceed the stated dose or the duration of treatment. Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is hypersensitivity to the product. Do not use the product within 48 hours before expected parturition in cows. Do not administer to pregnant mares. Do not administer to pregnant sows, gilts at mating and in breeding boars.

Special warnings for each target species

Non-steroidal, anti-inflammatory drugs are not permitted under the rules of Racing and under rules covering other competitive events. The Royal College of Veterinary Surgeons has given advice to the Veterinary Profession regarding the use of anti-inflammatory drugs in competing horses. It states that “if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing, he should feel sure that he has catered for all but the most exceptional case”. Do not exceed the recommended dose or duration of treatment.

Special precautions for use

Avoid intra-arterial injection.

NSAIDS are known to have the potential to delay parturition through a tocolytic effect by inhibiting prostaglandins that are important in signalling the initiation of parturition. The use of the product in the immediate post-partum period may interfere with uterine involution and expulsion of foetal membranes resulting in retained placentae. See also section "Use during pregnancy and lactation". Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management. Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock. It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered. The cause of colic should be determined and treated with concurrent therapy. The product should not be used in piglets weighing less than 6 kg.

Operator warnings:

Avoid contact with skin or eyes. In case of skin contact, wash exposed area with water. In case of eye contact, wash eyes thoroughly with clean water and seek medical advice. Take care against accidental self injection. Wash hands after use.

Adverse reactions

Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID). Untoward effects include gastro-intestinal irritation, ulceration and, in dehydrated or hypovolaemic animals, potential for renal damage. In pigs transient irritation may occur at the injection site, this resolves spontaneously within 14 days.

Use during pregnancy, lactation or lay

The product may be used in pregnant and lactating cattle. The product should only be administered within the first 36 hours post-partum following a benefit/risk assessment performed by the responsible veterinarian and treated animals should be monitored for retained placentae. Do not use in pregnant mares or pregnant sows. Safety studies in pregnant mares and pregnant sows have not been conducted.

Interactions

Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects. Concurrent administration of potentially nephrotoxic drugs should be avoided.

Amounts to be administered and administration route

Cattle

2 ml per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) administered intravenously. Repeat as necessary at 24 hour intervals for up to 5 consecutive days.

Horses

By intravenous injection for musculo-skeletal disorders at the following rate:

1 ml per 45 kg bodyweight (1.1 mg flunixin/kg) once daily for up to 5 days according to clinical response.

By intravenous injection for colic at the following rate: 1ml per 45 kg bodyweight (1.1 mg flunixin/kg) repeated once or twice if colic recurs. For the treatment of endotoxaemia or septic shock associated with gastric torsion and with other conditions in which the circulation of blood to the gastro-intestinal tract is compromised: 0.25 mg/kg every 6-8 hours, by intravenous injection.

Pigs

2 ml per 45 kg bodyweight (equivalent to 2.2 mg flunixin/kg) once by intramuscular injection, in the neck, in conjunction with appropriate antimicrobial therapy. The injection volume should be limited to a maximum of 5 ml per injection site. An appropriately graduated syringe must be used to allow accurate administration of the required dose volume. This is particularly important when injecting small volumes. When intramuscular injection is used, the dose should be divided between two injection sites on either side of the neck. In order to prevent excessive broaching of the rubber stopper, it is not recommended that the stopper is broached more than 25 times.

Overdose

Overdosage studies in the target species have shown the product to be well-tolerated. Flunixin meglumine is a non-steroidal anti-inflammatory drug.

Overdosage is associated with gastrointestinal toxicity. Concurrent use of nephrotoxic drugs should be avoided.

Withdrawal periods

Animals must not be slaughtered for human consumption during treatment.

Cattle: 5 days from the last treatment.

Horses: 7 days from the last treatment.

Pigs: 22 days from the last treatment.

Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 24 hours from the last treatment.

Pharmacological particulars

Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic activities.

Pharmaceutical particulars

Excipients

Phenol, Diethanolamine, Disodium Edetate dihydrate, Sodium Formaldehyde sulfoxylate dihydrate, Propylene Glycol, Hydrochloric acid 2.0N and Water for injection.

Major incompatibilities

Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects. Concurrent administration of potential nephrotoxic drugs should be avoided.

Shelf life

3 years.

Following withdrawal of the first dose, use within 28 days.

Discard unused material.

Special precautions for storage

Do not store above 25°C. Do not freeze.

Immediate packaging

Pack Sizes: 50 ml and 100 ml vials.

Containers: Clear Type I glass vials, molded.

Closures: Chlorobutyl rubber stopper with aluminium cap - one piece with tear-off centre.

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

-

Marketing authorisation number

Vm 01708/4582.

Date of the first authorisation or date of renewal

27 August 2007.

Date of revision of the text

July 2012.

Any other information

Nil

Legal category

POM-V

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Questions & Answers for Finadyne for Horses

There are currently no questions for Finadyne for Horses - be the first to ask one!

Ask A Question